<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anaphylaxis: Acute diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anaphylaxis: Acute diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anaphylaxis: Acute diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronna L Campbell, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Kelso, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ron M Walls, MD, FRCPC, FAAEM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1929228973"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anaphylaxis is an acute, potentially life-threatening, systemic hypersensitivity reaction caused by the sudden release of mast cell mediators [<a href="#rid1">1</a>]. It most often results from immunoglobulin E (IgE) mediated reactions to foods, drugs, and insect stings, but any agent capable of inciting a sudden, systemic degranulation of mast cells can induce it [<a href="#rid2">2</a>]. It can be difficult to recognize because it can mimic other conditions and is variable in its presentation. This topic will review the signs and symptoms of anaphylaxis, diagnostic criteria, and common causes and contributory factors. Laboratory tests that may be helpful in confirming the diagnosis are also briefly discussed.</p><p>The acute treatment of anaphylaxis, pathophysiology, and other related topics are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/386.html" rel="external">"Pathophysiology of anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5750.html" rel="external">"Anaphylaxis in infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>.)</p><p></p><p class="headingAnchor" id="H2044476951"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>In industrialized countries, the estimated lifetime prevalence of anaphylaxis from all causes is between 0.05 and 2 percent in the general population, and the rate of occurrence is increasing [<a href="#rid2">2-5</a>]. In the United States, the reported lifetime prevalence of anaphylaxis is at least 1.6 percent, based on strict clinical diagnostic criteria [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4007691360"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Anaphylaxis is defined as a serious allergic or hypersensitivity reaction that is usually rapid in onset and may cause death [<a href="#rid1">1,7</a>].</p><p class="headingAnchor" id="H2022441051"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of anaphylaxis is based primarily upon clinical symptoms and signs, as well as a detailed description of the acute episode, including antecedent activities and events occurring within the preceding minutes to hours. Recognition of the variable and atypical presentations of anaphylaxis is critical to providing effective therapy in the form of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, as well as reducing over-reliance on second-line medications, such as antihistamines and glucocorticoids, that are not lifesaving in anaphylaxis [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H1914347526"><span class="h2">NIAID/FAAN diagnostic criteria</span><span class="headingEndMark"> — </span>In 2006, diagnostic criteria for anaphylaxis were published by a multidisciplinary group of international experts and representatives from 13 professional, governmental, and lay organizations. The criteria were designed to help clinicians recognize the full spectrum of symptoms and signs that constitute anaphylaxis [<a href="#rid7">7</a>].</p><p>This group identified three diagnostic criteria for anaphylaxis, each reflecting a different clinical presentation  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. Anaphylaxis is highly likely when any <strong>one</strong> of the following three criteria is fulfilled.</p><p class="headingAnchor" id="H3500754922"><span class="h3">Criterion 1</span><span class="headingEndMark"> — </span>Acute onset of an illness (minutes to several hours) involving the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)<strong> and at least one of the following</strong>:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced blood pressure (BP) or associated symptoms and signs of end-organ malperfusion (eg, hypotonia [collapse], syncope, incontinence)</p><p></p><p>Note that skin symptoms and signs are present in up to 90 percent of anaphylactic episodes. This criterion will therefore frequently be helpful in making the diagnosis.</p><p class="headingAnchor" id="H3651158454"><span class="h3">Criterion 2</span><span class="headingEndMark"> — </span>Two or more of the following that occur rapidly after exposure <strong>to a likely allergen for that patient</strong> (minutes to several hours):</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced BP or associated symptoms and signs of end-organ malperfusion (eg, hypotonia [collapse], syncope, incontinence)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent gastrointestinal symptoms and signs (eg, crampy abdominal pain, vomiting)</p><p></p><p>Criterion 2 incorporates gastrointestinal symptoms in addition to skin symptoms, respiratory symptoms, and reduced BP. It is applied to patients with exposure to a substance that is a likely allergen for them.</p><p class="headingAnchor" id="H2680847136"><span class="h3">Criterion 3</span><span class="headingEndMark"> — </span>Reduced BP after exposure <strong>to a known allergen for that patient</strong> (minutes to several hours):</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced BP in adults is defined as a systolic BP of less than 90 mmHg or greater than 30 percent decrease from that person's baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In infants and children, reduced BP is defined as low systolic BP (age specific) or greater than 30 percent decrease in systolic BP.</p><p></p><p class="bulletIndent1">Low systolic BP for children is defined as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less than 70 mmHg from 1 month up to 1 year</p><p class="bulletIndent2"><span class="glyph">•</span>Less than (70 mmHg + [2 x age]) from 1 to 10 years</p><p class="bulletIndent2"><span class="glyph">•</span>Less than 90 mmHg from 11 to 17 years</p><p></p><p>Note that criterion 3 is intended to detect anaphylactic episodes in which only one organ system is involved and is applied to patients who have been exposed to a substance to which they are known to be allergic (for example, hypotension or shock after an insect sting).</p><p>There will be patients who do not fulfill any of these criteria but for whom the administration of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is appropriate. As an example, it would be appropriate to administer epinephrine to a patient with a history of severe anaphylaxis to peanut who presents with urticaria and flushing that developed within minutes of a known or suspected ingestion of peanut [<a href="#rid7">7</a>].</p><p>In a prospective study of 174 children and adults presenting to the emergency department with allergic reactions or suspected anaphylaxis, the criteria above had a sensitivity of 95 percent and a specificity of 71 percent [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1898772157"><span class="h2">World Allergy Organization criteria</span><span class="headingEndMark"> — </span>The World Allergy Organization proposed amended criteria in 2020, with the intent of simplifying the diagnosis by combining features of the three criteria above into two [<a href="#rid1">1</a>].</p><p>According to these amended criteria, anaphylaxis is highly likely when either <strong>one</strong> of the following two criteria is fulfilled [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3414110812"><span class="h3">Criterion 1</span><span class="headingEndMark"> — </span>Acute onset of an illness (minutes to several hours) with simultaneous involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) and at least one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circulatory compromise: reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia, collapse, syncope, incontinence)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe gastrointestinal symptoms (eg, severe crampy abdominal pain, repetitive vomiting), especially after exposure to nonfood allergens</p><p></p><p class="headingAnchor" id="H751787522"><span class="h3">Criterion 2</span><span class="headingEndMark"> — </span>Acute onset of hypotension, bronchospasm, or laryngeal involvement after exposure to a known or highly probable allergen for that patient (minutes to several hours), even in the absence of typical skin involvement:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypotension </strong>– Hypotension is defined as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults and children &gt;10 years </strong>– Decrease in systolic BP &gt;30 percent from that person's baseline <strong>or </strong>systolic BP &lt;90 mmHg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants and children &lt;10 years – </strong>Decrease in systolic BP &gt;30 percent from that person's baseline <strong>or</strong>: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age 1 month to 1 year </strong>– Less than 70 mmHg.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age 1 to 10 years </strong>– Less than (70 mmHg + [2 x age]).</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age 11 to 17 years </strong>– Less than 90 mmHg from 11 to 17 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchospasm </strong>– The definition of bronchospasm excludes lower respiratory symptoms triggered by common inhalant allergens or food allergens perceived to cause "inhalational" reactions in the absence of ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laryngeal involvement – </strong>Examples of laryngeal involvement include stridor, vocal changes, and odynophagia.</p><p></p><p class="headingAnchor" id="H3159936636"><span class="h1">SYMPTOMS AND SIGNS</span></p><p class="headingAnchor" id="H2571918616"><span class="h2">Common presentations</span><span class="headingEndMark"> — </span>Anaphylaxis may present with various combinations of approximately 40 potential symptoms and signs  (<a class="graphic graphic_table graphicRef66333" href="/d/graphic/66333.html" rel="external">table 2</a>) [<a href="#rid1">1,2,7,10-13</a>]. Recurring anaphylactic episodes in the same patient are likely to be of the same severity and follow the same sequence of symptoms as previous episodes [<a href="#rid14">14</a>]. Common presentations of anaphylaxis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin and mucosal symptoms and signs, which occur in up to 90 percent of episodes, including generalized hives, itching or flushing, swollen lips-tongue-uvula, periorbital edema, or conjunctival swelling. However, urticaria, flushing and itching may have resolved by the time the patient reaches a medical facility, so it is important to ask about skin findings at the start of the reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory symptoms and signs, which occur in up to 85 percent of episodes, including nasal discharge, nasal congestion, sneezing, itching of the throat and ear canals, change in voice quality, sensation of throat closure or choking, stridor, shortness of breath, wheeze, or cough.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal symptoms and signs, which occur in up to 45 percent of episodes, including nausea, vomiting, diarrhea, and crampy abdominal pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular symptoms and signs, which occur in up to 45 percent of episodes, including hypotonia (collapse), syncope, incontinence, dizziness, tachycardia, and hypotension.</p><p></p><p class="headingAnchor" id="H2756004582"><span class="h2">Range of severity</span><span class="headingEndMark"> — </span>Anaphylaxis is unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, angiotensin II, endothelin, and others), or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death [<a href="#rid11">11</a>]. At the onset of an anaphylactic episode, it is not possible to predict how severe it will become, how rapidly it will progress, and whether it will resolve promptly and completely or become biphasic or protracted, because the factors that determine the course of anaphylaxis in an individual patient are not fully understood. Thus, early administration of epinephrine is essential to prevent the progression to life-threatening manifestations. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Fatal anaphylaxis is rare [<a href="#rid15">15</a>]. Risk factors vary depending upon the trigger and include older age, preexisting cardiovascular morbidity, and delayed administration of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid15">15</a>]. The immediate cause of death is usually either asphyxiation due to upper or lower airway obstruction or cardiovascular collapse [<a href="#rid8">8,16-23</a>].</p><p>Death from anaphylaxis can occur within minutes. In a series of 164 cases of fatal anaphylaxis, the median time interval between onset of symptoms and respiratory or cardiac arrest was 5 minutes in iatrogenic anaphylaxis (usually due to anesthetics, intravenous medications, and contrast media), 15 minutes in stinging insect venom-induced anaphylaxis, and 30 minutes in food-induced anaphylaxis [<a href="#rid8">8</a>]. A more detailed review of fatal anaphylaxis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis"</a>.)</p><p class="headingAnchor" id="H2246678592"><span class="h2">Temporal patterns</span><span class="headingEndMark"> — </span>Anaphylaxis is usually characterized by a defined exposure to a potential cause, followed usually within seconds to minutes but rarely up to hours later, by rapid onset, evolution, and ultimate resolution of symptoms and signs.</p><p class="headingAnchor" id="H214089430"><span class="h3">Uniphasic anaphylaxis</span><span class="headingEndMark"> — </span>Uniphasic anaphylactic reactions are the most common type, accounting for an estimated 95 percent of all episodes. A uniphasic response typically peaks within hours after symptom onset and then either resolves spontaneously or after treatment, usually within several hours [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H3606062418"><span class="h3">Biphasic anaphylaxis</span><span class="headingEndMark"> — </span>Biphasic anaphylaxis is defined as a recurrence of symptoms meeting anaphylaxis diagnostic criteria that develops within 1 to 48 hours following the apparent resolution of the initial anaphylactic episode with no additional exposure to the causative agent [<a href="#rid26">26</a>]. Contemporary literature suggests that biphasic reactions occur in approximately 5 percent of cases. Recurrent symptoms typically occur within 12 hours after resolution of the initial symptoms. Greater severity in the initial phase and need for more than one dose of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> may be risk factors for biphasic anaphylaxis [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/396.html" rel="external">"Biphasic and protracted anaphylaxis"</a>.)</p><p class="headingAnchor" id="H2375024614"><span class="h3">Protracted anaphylaxis</span><span class="headingEndMark"> — </span>A protracted or persistent anaphylactic reaction lasts hours to days without clearly resolving completely. (See  <a class="medical medical_review" href="/d/html/396.html" rel="external">"Biphasic and protracted anaphylaxis", section on 'Protracted anaphylaxis'</a>.)</p><p class="headingAnchor" id="H691812788"><span class="h3">Refractory anaphylaxis</span><span class="headingEndMark"> — </span>Refractory anaphylaxis is defined as the persistence of anaphylaxis following appropriate <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> dosing with three or more appropriate doses of epinephrine or initiation of an intravenous epinephrine infusion along with symptom-directed medical management (eg, intravenous fluids for hypotension) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/396.html" rel="external">"Biphasic and protracted anaphylaxis", section on 'Refractory anaphylaxis'</a>.)</p><p class="headingAnchor" id="H1880583577"><span class="h3">Delayed anaphylaxis</span><span class="headingEndMark"> — </span>The onset of anaphylaxis can be delayed (ie, beginning hours rather than minutes after exposure to the causative agent) as can be observed in cases of alpha-gal syndrome, an increasingly recognized food allergy [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/2393.html" rel="external">"Allergy to meats", section on 'Alpha-gal'</a>.)</p><p class="headingAnchor" id="H349993124"><span class="h1">DIAGNOSTIC PITFALLS</span><span class="headingEndMark"> — </span>Anaphylaxis is not always easy to recognize clinically. The patterns of target organ involvement are variable and may differ among individuals, as well as among episodes in the same individual. Anaphylaxis is likely underdiagnosed and under-reported for a variety of reasons [<a href="#rid11">11,13,28,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Some health care professionals remain reluctant to diagnose anaphylaxis in the absence of hypotension or shock, even though changes in blood pressure (BP) are not required for the diagnosis according to criterion 1 or criterion 2 [<a href="#rid7">7</a>]. In fact, it is important to recognize anaphylaxis in its earlier stages because, once shock has developed, anaphylaxis may be much more difficult to treat. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Epinephrine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension may go undetected when measured very early in the course of the episode (when compensated by reflex tachycardia), when the initial BP measurement is obtained after <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> administration, or when an inappropriately small BP cuff is used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-appropriate standards for normal BP must be used for children and infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many of the dramatic physical signs associated with hypoxia and hypotension in anaphylaxis are nonspecific, such as dyspnea, stridor, wheeze, confusion, collapse, unconsciousness, and incontinence  (<a class="graphic graphic_table graphicRef66333" href="/d/graphic/66333.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin or mucosal symptoms and signs (such as hives, itching, flushing, and angioedema), which are helpful in making the diagnosis, are absent or unrecognized in up to 10 percent of all episodes. Skin symptoms and signs may be absent if a patient has taken an H1 antihistamine. They may also be missed if an individual cannot describe itching or is not undressed and fully examined during the episode or in patients who are draped during surgery [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylaxis may be difficult to recognize or may not be considered in certain clinical situations, such as situations in which dramatic physiologic shifts are occurring (eg, hemodialysis, surgery, childbirth). In addition, the inability of the patient to communicate the presence of early symptoms (eg, if anesthetized, sedated, or unconscious) also impedes prompt recognition of anaphylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anaphylaxis in a patient with asthma may be mistaken for an asthma exacerbation if accompanying skin symptoms and signs, such as itching or hives, mucosal, tongue, or lip edema, or dizziness suggestive of impending shock, are overlooked [<a href="#rid11">11</a>]. Of note, patients with isolated wheezing after exposure to a highly likely or known trigger for that patient would meet World Allergy Organization (WAO) diagnostic criteria for anaphylaxis (excluding inhalant allergens or food allergens perceived to cause an "inhalational" reaction when no ingestion occurred).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients experiencing their first episode may not recognize the symptoms as anaphylaxis. As a result, they may not report symptoms fully or may focus on one prominent symptom (eg, unless specifically asked, a patient presenting with vomiting may not report that the episode was preceded by diffuse itching).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The above factors are further compounded in patients with neurologic, psychiatric, or psychologic problems or those who take medications or substances, such as a sedating H1 antihistamine, ethanol, or recreational drugs that potentially impair cognition and judgment, making anaphylaxis symptoms difficult to recognize [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H287552937"><span class="h1">CAUSES AND MECHANISMS</span><span class="headingEndMark"> — </span>Most anaphylactic episodes have an immunologic mechanism involving IgE. Foods are the most common cause in children, while medications and insect stings are more common causes in adults. The table provides a more comprehensive list of potential anaphylaxis causes, categorized by causative mechanism  (<a class="graphic graphic_table graphicRef70667" href="/d/graphic/70667.html" rel="external">table 3</a>) [<a href="#rid7">7,10,13,30</a>].</p><p>In this review, the term "anaphylaxis" applies to all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute systemic reactions involving IgE-dependent mechanisms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute systemic reactions that occur due to direct (nonimmunologic) release of histamine and other mediators from mast cells and basophils, formerly called "anaphylactoid reactions" (eg, after exercise, exposure to cold, administration of radiocontrast media, etc).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute systemic reactions without any obvious cause or mechanism (idiopathic anaphylaxis). (See  <a class="medical medical_review" href="/d/html/387.html" rel="external">"Idiopathic anaphylaxis"</a>.)</p><p></p><p class="headingAnchor" id="H780233562"><span class="h1">CONTRIBUTORY FACTORS</span><span class="headingEndMark"> — </span>Comorbidities and concurrent medications may impact the severity of symptoms and signs and response to treatment in patients with anaphylaxis  (<a class="graphic graphic_table graphicRef65161" href="/d/graphic/65161.html" rel="external">table 4</a>) [<a href="#rid12">12,13,31</a>].</p><p class="headingAnchor" id="H375971479"><span class="h2">Comorbidities</span><span class="headingEndMark"> — </span>Asthma, cardiovascular disease, older age, and medication as a trigger are important risk factors for a poor outcome from anaphylaxis [<a href="#rid16">16,32,33</a>]. Other disorders may also increase risk:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent asthma is a risk factor for anaphylaxis [<a href="#rid34">34,35</a>]. Asthma is also associated with increased risk of death from anaphylaxis, especially in adolescents and young adults with poorly controlled disease [<a href="#rid8">8,16-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease is an important risk factor for death from anaphylaxis in middle-aged and older individuals [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other respiratory diseases (eg, chronic obstructive pulmonary disease [COPD], interstitial lung disease, or pneumonia) are also risk factors for severe or fatal anaphylaxis in older adults [<a href="#rid21">21,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute infection, such as an upper respiratory tract infection, fever, emotional stress, exercise, disruption of routine, and premenstrual status, may also increase the risk. With the exception of exercise, these amplifying factors have not been systematically studied in the context of anaphylaxis [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H1096757966"><span class="h2">Concurrent medications</span><span class="headingEndMark"> — </span>Concurrent administration of certain medications, such as beta-adrenergic blockers, angiotensin-converting enzyme (ACE) inhibitors, and alpha-adrenergic blockers, may increase the likelihood of severe or fatal anaphylaxis. These medications may also interfere with the patient's ability to respond to treatment and with the patient's compensatory physiologic responses  (<a class="graphic graphic_table graphicRef65161" href="/d/graphic/65161.html" rel="external">table 4</a>) [<a href="#rid33">33,37-39</a>].</p><p>A systematic review and meta-analysis of observational studies found that beta blockers and ACE inhibitors increased the severity of anaphylaxis but not the presence of new cases of anaphylaxis. However, the quality of the evidence was rated as low, and the authors were not able to adjust for concomitant cardiovascular disease, which may have, wholly or in part, been the explanation for the relationship. Further, they acknowledge that the benefit of these medications to patients may outweigh any increased risk for anaphylaxis severity [<a href="#rid40">40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-adrenergic blockers are sometimes associated with severe anaphylaxis and may also potentially make anaphylaxis more difficult to treat. They can theoretically cause unopposed alpha-adrenergic effects, leading to paradoxical hypertension, as well as reduce the bronchodilator and cardiovascular responses to beta-adrenergic stimulation by endogenous or exogenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Glucagon for patients taking beta blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-adrenergic blockers may decrease the effects of endogenous or exogenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> at alpha-adrenergic receptors, potentially making anaphylaxis less responsive to the alpha-adrenergic effects of epinephrine [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ACE inhibitors block the effect of angiotensin, a compensatory response, and also block the degradation of kinins, which are active in the production of symptoms and signs [<a href="#rid39">39,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an emergency department study, use of antihypertensive medications in aggregate (beta blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, or diuretics) by patients with anaphylaxis was associated with increased organ system involvement and increased odds of hospital admission, independent of age, sex, suspected cause, or preexisting lung disease [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of anaphylaxis patients enrolled in a European national registry demonstrated that the combination of ACE inhibitors and beta blockers increased the risk of more severe anaphylaxis [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol, nonsteroidal antiinflammatory drugs (NSAIDs), and opiates can exacerbate anaphylaxis symptoms by causing nonimmunologic mast cell activation [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H4053318931"><span class="h1">LABORATORY TESTS</span><span class="headingEndMark"> — </span>Anaphylaxis is a clinical diagnosis, and treatment cannot await laboratory confirmation. When the cause of the observed symptoms is in doubt, treatment for anaphylaxis is initiated. The clinical diagnosis can sometimes be retrospectively supported by documentation of elevated concentrations of serum or plasma total tryptase or plasma histamine, although the results of these tests are not immediately available to the treating clinician [<a href="#rid44">44-46</a>]. It is critical to obtain blood samples for measurement of these mast cell and basophil mediators soon after the onset of symptoms because elevations are transient. Instructions for proper collection of samples are provided in the table  (<a class="graphic graphic_table graphicRef72041" href="/d/graphic/72041.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum or plasma total tryptase</strong> – The standardized assay for measurement of total serum or plasma tryptase is widely available in clinical laboratories (normal range 1 to 11.4 ng/mL). In infants under age six months, normal baseline total tryptase concentrations are higher than they are in older infants, children, and adults [<a href="#rid45">45,47</a>]. Optimally, the blood sample for tryptase measurement needs to be obtained within 15 minutes to 3 hours of symptom onset. However, tryptase may remain elevated for six or more hours after the onset and therefore may still be informative if obtained after three hours.</p><p></p><p class="bulletIndent1">Tryptase elevations are more likely to be detected in anaphylaxis from stinging insect venoms or medications and during reactions that involve hypotension [<a href="#rid44">44,48</a>].</p><p></p><p class="bulletIndent1">A tryptase level that is within normal limits cannot be used to refute the clinical diagnosis of anaphylaxis [<a href="#rid31">31</a>]. The history is more important than the test results. As an example, in individuals with food-induced anaphylaxis or in patients who are normotensive, tryptase levels are seldom elevated, even in optimally timed blood samples obtained within 15 minutes to 3 hours of symptom onset [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Serial measurements of total tryptase in serum or plasma over several hours may increase the sensitivity and the specificity of the tests. In a prospective study, sequential serum tryptase concentrations were measured in 102 adults with anaphylaxis [<a href="#rid49">49</a>]. Tryptase levels 1 to 2 hours after onset of the episode were significantly elevated (19.3±15.4 mcg/L) compared with levels at 4 to 6 hours and at 12 to 24 hours after the onset and at baseline (all &lt;11.4 mcg/L). However, tryptase was not elevated in 37 percent of cases.</p><p></p><p class="bulletIndent1">A rise in total tryptase levels above baseline may be more sensitive than a single measurement. In adults with venom-induced allergic reactions, an increase in tryptase of ≥2.0 mcg/L was 73 percent sensitive and 98 percent specific for anaphylaxis [<a href="#rid50">50</a>]. Sixty percent of children with anaphylaxis had an elevation of ≥2 + 1.2 x baseline tryptase levels [<a href="#rid51">51</a>]. Note that, in most cases, the patient's baseline tryptase is not initially known and must be established after all symptoms have resolved and the patient is in their usual state of health. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a>.)</p><p></p><p class="bulletIndent1">If a tryptase level obtained 24 or more hours after resolution of symptoms is still elevated, the patient should be referred to an allergy/immunology specialist for evaluation of possible systemic mastocytosis or a mast cell activation syndrome. Patients with mast cell disorders may have hypotensive reactions to insect stings, even in the absence of IgE-mediated allergy [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/15715.html" rel="external">"Mast cell disorders: An overview"</a>.)</p><p></p><p class="bulletIndent1">The real-world utility of tryptase measurements was assessed in a study of 426 cases of suspected anaphylaxis admitted to three emergency departments over the course of one year [<a href="#rid48">48</a>]. Tryptase was obtained in 141 cases (33 percent) at a mean of 4.75 hours after estimated onset of symptoms and again after resolution in 23 cases. In this setting, a tryptase above 12.4 ng/mL had a high specificity (88 percent) and positive predictive value (0.93) and a low sensitivity (28 percent) and negative predictive values (0.17). Serum tryptase was more likely to be elevated in patients with hypotension, as has been observed in other studies.</p><p></p><p class="bulletIndent1">Hereditary alpha-tryptasemia (HaT) is a genetic trait caused by increased copy number of genes encoding alpha-tryptase and is found in approximately 5 percent of healthy individuals. Conflicting studies have suggested that HaT may [<a href="#rid53">53</a>] or may not [<a href="#rid54">54</a>] be a risk factor for more severe anaphylaxis. (See  <a class="medical medical_review" href="/d/html/135236.html" rel="external">"Hereditary alpha-tryptasemia"</a>.)</p><p></p><p class="bulletIndent1">Note that tryptase can be elevated in numerous other conditions including myeloproliferative disorders and nonanaphylactic shock [<a href="#rid55">55,56</a>]. The differential of an elevated tryptase level is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Elevations of tryptase in nonanaphylactic patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma histamine</strong> – Plasma histamine levels typically peak within 5 to 15 minutes of the onset of anaphylaxis symptoms and then decline to baseline by 60 minutes due to rapid metabolism by N-methyltransferase and diamine oxidase. Elevated plasma histamine levels correlate with anaphylaxis symptoms and signs and are more likely to be increased than are total serum tryptase levels [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1">Measurement of this mediator may be useful in cases of anaphylaxis occurring in a hospital setting in which blood samples can be collected soon after the onset of symptoms. In many cases of anaphylaxis in the community, however, it is not practical to measure histamine, because often by the time the patient reaches the emergency department, levels have returned to baseline [<a href="#rid31">31,44</a>].</p><p></p><p class="bulletIndent1">Histamine should be measured in plasma rather than serum because clotting may result in release of histamine that is artifactual and only occurs ex vivo due to compromised basophil cell membranes. Blood samples for histamine require special handling. Draw blood through a wide-bore needle, keep it cold at all times, centrifuge it immediately, and freeze the plasma promptly [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1">Histamine and histamine metabolites can sometimes be detected in the urine following anaphylaxis, and elevations are less fleeting than elevations in plasma histamine. However, a 24-hour urine collection started as soon as possible after the reaction begins is required. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Histamine metabolites'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential future tests</strong> – The development of a rapid, sensitive, specific laboratory test or panel of tests that helps clinicians to confirm the diagnosis of anaphylaxis in real time remains an important goal [<a href="#rid10">10,31</a>].</p><p></p><p class="bulletIndent1">A laboratory test for mature beta-tryptase, a better marker of mast cell activation than total tryptase (which measures constitutively secreted alpha-tryptase in addition to beta-tryptase) has been developed, although it is not widely available [<a href="#rid10">10</a>]. Testing for mature beta-tryptase is reviewed separately. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a>.)</p><p></p><p class="bulletIndent1">Other potential markers of mast cell and/or basophil degranulation, such as platelet-activating factor, mast cell carboxypeptidase A3, chymase, and basogranulin, are under investigation [<a href="#rid31">31,46,57-59</a>].</p><p></p><p class="headingAnchor" id="H4009997729"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Approximately 40 other diseases and conditions might need to be considered in the differential diagnosis of anaphylaxis  (<a class="graphic graphic_table graphicRef65677" href="/d/graphic/65677.html" rel="external">table 6</a>) [<a href="#rid60">60-67</a>]. The most common disorders in the differential diagnosis include acute generalized urticaria and/or angioedema, acute asthma exacerbations, syncope/faint, and anxiety/panic attacks. These are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a> and  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5750.html" rel="external">"Anaphylaxis in infants", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H2621867084"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105526.html" rel="external">"Society guideline links: Anaphylaxis"</a>.)</p><p class="headingAnchor" id="H4083160552"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15336.html" rel="external">"Patient education: Anaphylaxis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/368.html" rel="external">"Patient education: Anaphylaxis symptoms and diagnosis (Beyond the Basics)"</a>)</p><p></p><p>Other sources of accurate patient information that are accessible through the internet include the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aaaai.org%2F&amp;token=RxBqIaK4IjVvTPMpPUJnutMMeVmA8xmPyYsKJbu1ibM%3D&amp;TOPIC_ID=106778" target="_blank">American Academy of Allergy, Asthma &amp; Immunology</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facaai.org%2F&amp;token=tZrUlmu6F5AD6Dd2hqyGsjeNIy2IZFShjUghjy6nBrI%3D&amp;TOPIC_ID=106778" target="_blank">American College of Allergy, Asthma &amp; Immunology</a> [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H3801473448"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Anaphylaxis is an acute, potentially life-threatening, multisystem syndrome caused by the sudden release of mast cell mediators into the systemic circulation. It most often results from immunoglobulin E (IgE) mediated reactions to foods, drugs, and insect stings, but any agent capable of inciting a sudden, systemic degranulation of mast cells can result in anaphylaxis. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – The diagnosis of anaphylaxis is based on clinical criteria. There are three clinical criteria for the diagnosis of anaphylaxis, which reflect the different ways in which anaphylaxis may present. Anaphylaxis is highly likely when any <strong>one</strong> of the three criteria is fulfilled  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 1</a>). Simplified criteria were proposed in 2020. These diagnostic criteria do not replace clinical judgment, particularly for a patient with a prior episode of anaphylaxis. (See <a class="local">'NIAID/FAAN diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic pitfalls:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anaphylaxis may present with various combinations of as many as 40 potential symptoms and signs  (<a class="graphic graphic_table graphicRef66333" href="/d/graphic/66333.html" rel="external">table 2</a>). Although recognition of the clinical syndrome of anaphylaxis is usually straightforward, some cases may be difficult to diagnose because anaphylaxis can mimic many other disorders and can be variable in its presentation. (See <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prompt recognition is critical in anaphylaxis. In fatal anaphylaxis, median times to cardiorespiratory arrest are 5 minutes in iatrogenic anaphylaxis, 15 minutes in stinging insect venom-induced anaphylaxis, and 30 minutes in food-induced anaphylaxis. (See <a class="local">'Range of severity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anaphylaxis is unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators, or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death. At the onset of an anaphylactic episode, it is not possible to predict how severe it will become or how rapidly it will progress. For these reasons, early and definitive treatment of suspected anaphylaxis (with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>) is indicated. (See <a class="local">'Range of severity'</a> above and  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients and health care professionals commonly fail to recognize and diagnose anaphylaxis in its early stages when it is most responsive to treatment. In particular, there is a reluctance to diagnose anaphylaxis in the absence of hypotension, even though this sign is not required for the diagnosis and is uncommon in children with anaphylaxis or in food-induced anaphylaxis. (See <a class="local">'Diagnostic pitfalls'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism and causes</strong> – Anaphylaxis most often results from an IgE-mediated allergic reaction, although other mechanisms are possible. Foods are the most common cause in children, and medications and insect stings are the most common culprits in adults, although there is a rapidly expanding list of novel and/or unusual causes  (<a class="graphic graphic_table graphicRef70667" href="/d/graphic/70667.html" rel="external">table 3</a>). (See <a class="local">'Causes and mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Tryptase and histamine are released almost exclusively by mast cells and basophils and may be transiently elevated in patients with anaphylaxis. However, these results are not immediately available, and elevations of these mediators are not universal in anaphylaxis, so measurement of mediators is not included in the diagnostic criteria. Despite these limitations, the finding of elevated tryptase (serum or plasma) or histamine (plasma) suggests that the event was anaphylaxis and can be useful in excluding other causes of sudden severe cardiorespiratory symptoms. The blood sample for tryptase should be obtained within 15 minutes to 3 hours of symptom onset  (<a class="graphic graphic_table graphicRef72041" href="/d/graphic/72041.html" rel="external">table 5</a>). (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of anaphylaxis is broad  (<a class="graphic graphic_table graphicRef65677" href="/d/graphic/65677.html" rel="external">table 6</a>). Common disorders that can mimic anaphylaxis include acute generalized urticaria and/or angioedema, acute asthma exacerbations, syncope/faint, and anxiety/panic attacks. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2563359595"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge F Estelle R Simons, MD, FRCPC and Carlos Camargo, Jr, MD, DrPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.</a></li><li><a class="nounderline abstract_t">Yu JE, Lin RY. The Epidemiology of Anaphylaxis. Clin Rev Allergy Immunol 2018; 54:366.</a></li><li><a class="nounderline abstract_t">Motosue MS, Bellolio MF, Van Houten HK, et al. Increasing Emergency Department Visits for Anaphylaxis, 2005-2014. J Allergy Clin Immunol Pract 2017; 5:171.</a></li><li><a class="nounderline abstract_t">Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol 2015; 135:956.</a></li><li><a class="nounderline abstract_t">Michelson KA, Dribin TE, Vyles D, Neuman MI. Trends in emergency care for anaphylaxis. J Allergy Clin Immunol Pract 2020; 8:767.</a></li><li><a class="nounderline abstract_t">Wood RA, Camargo CA Jr, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol 2014; 133:461.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.</a></li><li><a class="nounderline abstract_t">Loprinzi Brauer CE, Motosue MS, Li JT, et al. Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis. J Allergy Clin Immunol Pract 2016; 4:1220.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.</a></li><li><a class="nounderline abstract_t">Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol 2014; 113:599.</a></li><li><a class="nounderline abstract_t">Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082.</a></li><li><a class="nounderline abstract_t">Slapnicar C, Lebovic G, McParland A, et al. Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis. J Allergy Clin Immunol Pract 2022; 10:534.</a></li><li><a class="nounderline abstract_t">Turner PJ, Jerschow E, Umasunthar T, et al. Fatal Anaphylaxis: Mortality Rate and Risk Factors. J Allergy Clin Immunol Pract 2017; 5:1169.</a></li><li><a class="nounderline abstract_t">Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.</a></li><li><a class="nounderline abstract_t">Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.</a></li><li><a class="nounderline abstract_t">Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.</a></li><li><a class="nounderline abstract_t">Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.</a></li><li><a class="nounderline abstract_t">Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009; 186:1.</a></li><li><a class="nounderline abstract_t">Yilmaz R, Yuksekbas O, Erkol Z, et al. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol 2009; 30:346.</a></li><li><a class="nounderline abstract_t">Kraft M, Scherer Hofmeier K, Ruëff F, et al. Risk Factors and Characteristics of Biphasic Anaphylaxis. J Allergy Clin Immunol Pract 2020; 8:3388.</a></li><li><a class="nounderline abstract_t">Lee S, Bellolio MF, Hess EP, et al. Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract 2015; 3:408.</a></li><li><a class="nounderline abstract_t">Dribin TE, Sampson HA, Camargo CA Jr, et al. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study. J Allergy Clin Immunol 2020; 146:1089.</a></li><li><a class="nounderline abstract_t">Commins SP, Jerath MR, Cox K, et al. Delayed anaphylaxis to alpha-gal, an oligosaccharide in mammalian meat. Allergol Int 2016; 65:16.</a></li><li><a class="nounderline abstract_t">Thomson H, Seith R, Craig S. Downstream consequences of diagnostic error in pediatric anaphylaxis. BMC Pediatr 2018; 18:40.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537.</a></li><li><a class="nounderline abstract_t">Worm M, Eckermann O, Dölle S, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int 2014; 111:367.</a></li><li><a class="nounderline abstract_t">Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.</a></li><li><a class="nounderline abstract_t">Motosue MS, Bellolio MF, Van Houten HK, et al. Risk factors for severe anaphylaxis in the United States. Ann Allergy Asthma Immunol 2017; 119:356.</a></li><li><a class="nounderline abstract_t">Worm M, Francuzik W, Renaudin JM, et al. Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy 2018; 73:1322.</a></li><li><a class="nounderline abstract_t">González-Pérez A, Aponte Z, Vidaurre CF, Rodríguez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010; 125:1098.</a></li><li><a class="nounderline abstract_t">Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol 2010; 104:371.</a></li><li><a class="nounderline abstract_t">Mulla ZD, Simons FE. Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study. BMJ Open 2013; 3.</a></li><li><a class="nounderline abstract_t">Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Watson A. Alpha adrenergic blockers and adrenaline. A mysterious collapse. Aust Fam Physician 1998; 27:714.</a></li><li><a class="nounderline abstract_t">Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.</a></li><li><a class="nounderline abstract_t">Tejedor-Alonso MA, Farias-Aquino E, Pérez-Fernández E, et al. Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies. J Allergy Clin Immunol Pract 2019; 7:879.</a></li><li><a class="nounderline abstract_t">Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337.</a></li><li><a class="nounderline abstract_t">Lee S, Hess EP, Nestler DM, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131:1103.</a></li><li><a class="nounderline abstract_t">Nassiri M, Babina M, Dölle S, et al. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015; 135:491.</a></li><li><a class="nounderline abstract_t">Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.</a></li><li><a class="nounderline abstract_t">Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.</a></li><li><a class="nounderline abstract_t">Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol 2013; 131:144.</a></li><li><a class="nounderline abstract_t">Belhocine W, Ibrahim Z, Grandné V, et al. Total serum tryptase levels are higher in young infants. Pediatr Allergy Immunol 2011; 22:600.</a></li><li><a class="nounderline abstract_t">Buka RJ, Knibb RC, Crossman RJ, et al. Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments. J Allergy Clin Immunol Pract 2017; 5:1280.</a></li><li><a class="nounderline abstract_t">Sala-Cunill A, Cardona V, Labrador-Horrillo M, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol 2013; 160:192.</a></li><li><a class="nounderline abstract_t">Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas 2004; 16:120.</a></li><li><a class="nounderline abstract_t">De Schryver S, Halbrich M, Clarke A, et al. Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors. J Allergy Clin Immunol 2016; 137:1138.</a></li><li><a class="nounderline abstract_t">Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015; 3:350.</a></li><li><a class="nounderline abstract_t">Lyons JJ, Chovanec J, O'Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021; 147:622.</a></li><li><a class="nounderline abstract_t">Chollet MB, Akin C. Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. J Allergy Clin Immunol 2022; 149:728.</a></li><li><a class="nounderline abstract_t">Francis A, Fatovich DM, Arendts G, et al. Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia. Emerg Med Australas 2018; 30:366.</a></li><li><a class="nounderline abstract_t">Lee AYS. Elevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review. Int Arch Allergy Immunol 2020; 181:357.</a></li><li><a class="nounderline abstract_t">Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.</a></li><li><a class="nounderline abstract_t">Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.</a></li><li><a class="nounderline abstract_t">Mochizuki A, McEuen AR, Buckley MG, Walls AF. The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation. J Allergy Clin Immunol 2003; 112:102.</a></li><li class="breakAll">Lieberman PL. Anaphylaxis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), St. Louis 2009. p.1027.</li><li><a class="nounderline abstract_t">Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55:193.</a></li><li><a class="nounderline abstract_t">Erem C, Kocak M, Onder Ersoz H, et al. Epinephrine-secreting cystic pheochromocytoma presenting with an incidental adrenal mass: a case report and a review of the literature. Endocrine 2005; 28:225.</a></li><li><a class="nounderline abstract_t">Ueda T, Oka N, Matsumoto A, et al. Pheochromocytoma presenting as recurrent hypotension and syncope. Intern Med 2005; 44:222.</a></li><li><a class="nounderline abstract_t">Becker K, Southwick K, Reardon J, et al. Histamine poisoning associated with eating tuna burgers. JAMA 2001; 285:1327.</a></li><li><a class="nounderline abstract_t">Daschner A, Alonso-Gómez A, Cabañas R, et al. Gastroallergic anisakiasis: borderline between food allergy and parasitic disease-clinical and allergologic evaluation of 20 patients with confirmed acute parasitism by Anisakis simplex. J Allergy Clin Immunol 2000; 105:176.</a></li><li><a class="nounderline abstract_t">Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692.</a></li><li><a class="nounderline abstract_t">Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.</a></li><li class="breakAll">The American College of Allergy, Asthma and Immunology. www.acaai.org (Accessed on August 13, 2009).</li><li class="breakAll">The American Academy of Allergy, Asthma and Immunology. www.aaaai.org (Accessed on August 13, 2009).</li></ol></div><div id="topicVersionRevision">Topic 106778 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33204386" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World allergy organization anaphylaxis guidance 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26357949" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Epidemiology of Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27818135" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Increasing Emergency Department Visits for Anaphylaxis, 2005-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25468198" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31466851" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Trends in emergency care for anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144575" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931122" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lessons for management of anaphylaxis from a study of fatal reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27406968" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176258" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461138" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anaphylaxis, killer allergy: long-term management in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25466802" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001253" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34933152" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888247" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fatal Anaphylaxis: Mortality Rate and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1294076" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fatal and near-fatal anaphylactic reactions to food in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150011" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fatalities due to anaphylactic reactions to foods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306354" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Further fatalities caused by anaphylactic reactions to food, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238794" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anaphylaxis: can we tell who is at risk of a fatal reaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349682" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378256" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal anaphylaxis: postmortem findings and associated comorbid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217731" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901808" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Postmortem findings after anaphylactic reactions to drugs in Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk Factors and Characteristics of Biphasic Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680923" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853640" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666477" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Delayed anaphylaxis to alpha-gal, an oligosaccharide in mammalian meat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29415679" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Downstream consequences of diagnostic error in pediatric anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765754" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anaphylaxis in infants: can recognition and management be improved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24939374" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602945" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk assessment in anaphylaxis: current and future approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958375" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for severe anaphylaxis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318637" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392483" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20486326" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23903813" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721322" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Allergy and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Alpha adrenergic blockers and adrenaline. A mysterious collapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895993" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30408615" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620826" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiovascular disease and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453138" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441633" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931288" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic value of tryptase in anaphylaxis and mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665778" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum tryptase levels in atopic and nonatopic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040367" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21736626" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Total serum tryptase levels are higher in young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888252" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018683" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239726" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Can serum mast cell tryptase help diagnose anaphylaxis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26478007" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858055" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32717252" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Heritable risk for severe anaphylaxis associated with increasedα-tryptase-encoding germline copy number at TPSAB1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174297" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hereditary alpha tryptasemia is not associated with specific clinical phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29094472" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32126554" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Elevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207562" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172172" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847486" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847486" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844500" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The flushing patient: differential diagnosis, workup, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16388097" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epinephrine-secreting cystic pheochromocytoma presenting with an incidental adrenal mass: a case report and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805711" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pheochromocytoma presenting as recurrent hypotension and syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255388" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Histamine poisoning associated with eating tuna burgers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629469" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gastroallergic anisakiasis: borderline between food allergy and parasitic disease-clinical and allergologic evaluation of 20 patients with confirmed acute parasitism by Anisakis simplex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841766" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493503" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Idiopathic anaphylaxis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
